Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperlipoproteinemia Type II | 29 | 2024 | 395 | 5.470 |
Why?
|
Dyslipidemias | 15 | 2023 | 868 | 4.760 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 20 | 2023 | 536 | 3.240 |
Why?
|
Cardiovascular Diseases | 45 | 2024 | 15498 | 2.670 |
Why?
|
Hypercholesterolemia | 13 | 2024 | 1141 | 2.350 |
Why?
|
Coronary Aneurysm | 12 | 2023 | 232 | 2.200 |
Why?
|
Cholesterol, LDL | 25 | 2024 | 2379 | 2.120 |
Why?
|
Mass Screening | 19 | 2024 | 5424 | 1.960 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 15 | 2022 | 3244 | 1.740 |
Why?
|
American Heart Association | 18 | 2024 | 1039 | 1.730 |
Why?
|
Atherosclerosis | 15 | 2024 | 3400 | 1.530 |
Why?
|
Cholesterol | 16 | 2023 | 2903 | 1.500 |
Why?
|
Triglycerides | 14 | 2022 | 2459 | 1.470 |
Why?
|
Lipids | 14 | 2023 | 3332 | 1.360 |
Why?
|
Health Behavior | 6 | 2021 | 2643 | 1.320 |
Why?
|
Cardiology | 10 | 2022 | 1656 | 1.220 |
Why?
|
Anticholesteremic Agents | 10 | 2023 | 967 | 1.190 |
Why?
|
Child | 95 | 2024 | 80079 | 1.110 |
Why?
|
Adolescent | 85 | 2024 | 88234 | 1.070 |
Why?
|
Hyperlipidemias | 7 | 2022 | 770 | 1.060 |
Why?
|
Hypertension | 14 | 2023 | 8529 | 1.060 |
Why?
|
Preventive Health Services | 6 | 2021 | 566 | 0.970 |
Why?
|
Nutrition Surveys | 12 | 2024 | 1723 | 0.960 |
Why?
|
Health Status Indicators | 2 | 2021 | 969 | 0.870 |
Why?
|
Guideline Adherence | 5 | 2017 | 2218 | 0.810 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2020 | 4007 | 0.780 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 2 | 2023 | 244 | 0.770 |
Why?
|
Pediatrics | 11 | 2022 | 3588 | 0.730 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2022 | 3415 | 0.720 |
Why?
|
Preventive Medicine | 2 | 2020 | 245 | 0.700 |
Why?
|
Heart Defects, Congenital | 6 | 2024 | 4671 | 0.700 |
Why?
|
Life Style | 9 | 2022 | 3904 | 0.680 |
Why?
|
Systemic Inflammatory Response Syndrome | 6 | 2023 | 619 | 0.680 |
Why?
|
Prevalence | 16 | 2024 | 15689 | 0.670 |
Why?
|
Directive Counseling | 1 | 2021 | 170 | 0.660 |
Why?
|
Practice Guidelines as Topic | 12 | 2020 | 7389 | 0.660 |
Why?
|
Risk Factors | 54 | 2024 | 74115 | 0.650 |
Why?
|
Humans | 174 | 2024 | 760617 | 0.620 |
Why?
|
Awareness | 2 | 2020 | 649 | 0.600 |
Why?
|
Heart Diseases | 7 | 2021 | 2778 | 0.600 |
Why?
|
United States | 52 | 2024 | 72272 | 0.580 |
Why?
|
Hyperglycemia | 2 | 2022 | 1375 | 0.580 |
Why?
|
Health Status | 5 | 2020 | 4075 | 0.560 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2018 | 241 | 0.540 |
Why?
|
Alanine Transaminase | 1 | 2019 | 601 | 0.520 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2019 | 385 | 0.510 |
Why?
|
Hypertriglyceridemia | 3 | 2019 | 293 | 0.510 |
Why?
|
Young Adult | 45 | 2024 | 59179 | 0.510 |
Why?
|
Creatine Kinase | 1 | 2017 | 685 | 0.490 |
Why?
|
Obesity | 20 | 2023 | 12933 | 0.470 |
Why?
|
Female | 92 | 2024 | 392148 | 0.470 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 2 | 2013 | 322 | 0.470 |
Why?
|
Diet, Fat-Restricted | 1 | 2017 | 329 | 0.460 |
Why?
|
Boston | 12 | 2023 | 9313 | 0.450 |
Why?
|
Male | 85 | 2024 | 360358 | 0.450 |
Why?
|
Urban Health | 1 | 2016 | 532 | 0.440 |
Why?
|
Women's Health | 3 | 2021 | 2065 | 0.440 |
Why?
|
Cholesterol, HDL | 7 | 2022 | 1810 | 0.440 |
Why?
|
Echocardiography | 8 | 2023 | 4987 | 0.430 |
Why?
|
Biosensing Techniques | 1 | 2019 | 647 | 0.430 |
Why?
|
Child, Preschool | 30 | 2024 | 42188 | 0.430 |
Why?
|
Coronary Vessels | 4 | 2020 | 3095 | 0.430 |
Why?
|
Patient Transfer | 1 | 2020 | 793 | 0.420 |
Why?
|
Muscular Diseases | 1 | 2017 | 553 | 0.410 |
Why?
|
Tobacco Smoke Pollution | 2 | 2016 | 819 | 0.410 |
Why?
|
Immunoglobulins, Intravenous | 7 | 2020 | 664 | 0.410 |
Why?
|
Risk Reduction Behavior | 9 | 2020 | 1110 | 0.400 |
Why?
|
Income | 2 | 2022 | 1870 | 0.390 |
Why?
|
Risk Assessment | 17 | 2023 | 23972 | 0.380 |
Why?
|
Blood Pressure | 12 | 2023 | 8472 | 0.380 |
Why?
|
Homozygote | 6 | 2024 | 1776 | 0.370 |
Why?
|
Equipment Design | 1 | 2019 | 3501 | 0.370 |
Why?
|
Blood Component Removal | 2 | 2024 | 132 | 0.370 |
Why?
|
Coronary Artery Disease | 6 | 2024 | 6403 | 0.370 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 3879 | 0.370 |
Why?
|
C-Reactive Protein | 8 | 2020 | 3822 | 0.350 |
Why?
|
Longevity | 1 | 2018 | 1064 | 0.350 |
Why?
|
Energy Intake | 2 | 2019 | 2132 | 0.350 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2020 | 12142 | 0.340 |
Why?
|
Disease Management | 1 | 2020 | 2506 | 0.330 |
Why?
|
Body Mass Index | 12 | 2020 | 12943 | 0.330 |
Why?
|
Thrombosis | 3 | 2020 | 2943 | 0.330 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2019 | 1390 | 0.320 |
Why?
|
Pulse | 1 | 2009 | 217 | 0.320 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3351 | 0.320 |
Why?
|
Health Promotion | 4 | 2021 | 2206 | 0.320 |
Why?
|
Carotid Artery Diseases | 1 | 2015 | 877 | 0.310 |
Why?
|
Dietary Supplements | 3 | 2020 | 3411 | 0.310 |
Why?
|
Research Report | 3 | 2016 | 367 | 0.300 |
Why?
|
Adult | 43 | 2024 | 220969 | 0.290 |
Why?
|
Counseling | 4 | 2022 | 1538 | 0.290 |
Why?
|
Advisory Committees | 3 | 2017 | 787 | 0.290 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2012 | 851 | 0.280 |
Why?
|
Age Factors | 10 | 2020 | 18381 | 0.280 |
Why?
|
Infant | 18 | 2024 | 36152 | 0.270 |
Why?
|
Policy Making | 2 | 2020 | 541 | 0.270 |
Why?
|
Delayed Diagnosis | 2 | 2021 | 463 | 0.270 |
Why?
|
Retrospective Studies | 22 | 2024 | 80566 | 0.250 |
Why?
|
Adiposity | 3 | 2018 | 1879 | 0.250 |
Why?
|
Fever | 3 | 2023 | 1618 | 0.240 |
Why?
|
Follow-Up Studies | 13 | 2024 | 39063 | 0.240 |
Why?
|
Myocarditis | 2 | 2022 | 788 | 0.230 |
Why?
|
Cross-Sectional Studies | 11 | 2022 | 26049 | 0.220 |
Why?
|
Feeding Behavior | 1 | 2015 | 3182 | 0.210 |
Why?
|
Evidence-Based Medicine | 3 | 2020 | 3680 | 0.210 |
Why?
|
Immunization | 2 | 2017 | 1217 | 0.200 |
Why?
|
Genetic Testing | 7 | 2024 | 3533 | 0.200 |
Why?
|
Endothelium, Vascular | 3 | 2019 | 4433 | 0.200 |
Why?
|
Apolipoproteins B | 3 | 2019 | 385 | 0.200 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1879 | 0.190 |
Why?
|
Food | 2 | 2016 | 768 | 0.190 |
Why?
|
Adipocytes | 1 | 2008 | 1187 | 0.190 |
Why?
|
Health Surveys | 5 | 2016 | 4037 | 0.180 |
Why?
|
Consensus | 4 | 2024 | 3117 | 0.180 |
Why?
|
Overweight | 2 | 2017 | 2417 | 0.180 |
Why?
|
Health Policy | 1 | 2013 | 2682 | 0.180 |
Why?
|
Warfarin | 2 | 2020 | 1477 | 0.170 |
Why?
|
Prospective Studies | 12 | 2021 | 54360 | 0.170 |
Why?
|
Registries | 6 | 2023 | 8207 | 0.170 |
Why?
|
Pulmonary Valve | 1 | 2024 | 411 | 0.170 |
Why?
|
Primary Prevention | 2 | 2021 | 1185 | 0.170 |
Why?
|
Hospitals, Pediatric | 2 | 2024 | 1859 | 0.170 |
Why?
|
Attitude to Health | 2 | 2020 | 2024 | 0.160 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 299 | 0.160 |
Why?
|
Nicotine | 1 | 2024 | 679 | 0.160 |
Why?
|
Stroke | 5 | 2024 | 9712 | 0.160 |
Why?
|
Atrioventricular Block | 1 | 2020 | 132 | 0.160 |
Why?
|
Diet, Sodium-Restricted | 1 | 2020 | 291 | 0.160 |
Why?
|
Lipoproteins | 2 | 2024 | 879 | 0.160 |
Why?
|
Folic Acid Antagonists | 1 | 1998 | 75 | 0.150 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 344 | 0.150 |
Why?
|
Food Supply | 1 | 2024 | 539 | 0.150 |
Why?
|
Chemoprevention | 1 | 2020 | 325 | 0.150 |
Why?
|
Treatment Outcome | 13 | 2024 | 64568 | 0.150 |
Why?
|
Canada | 2 | 2020 | 2118 | 0.150 |
Why?
|
Brachial Artery | 2 | 2010 | 366 | 0.150 |
Why?
|
Self Report | 3 | 2018 | 3723 | 0.150 |
Why?
|
Aortic Valve Insufficiency | 1 | 2022 | 576 | 0.150 |
Why?
|
Blood Pressure Determination | 2 | 2018 | 633 | 0.150 |
Why?
|
Ventricular Remodeling | 2 | 2017 | 1265 | 0.150 |
Why?
|
Proprotein Convertases | 2 | 2016 | 95 | 0.150 |
Why?
|
Infant, Newborn | 7 | 2024 | 26180 | 0.140 |
Why?
|
Goals | 1 | 2022 | 708 | 0.140 |
Why?
|
Continuity of Patient Care | 1 | 2024 | 1066 | 0.140 |
Why?
|
Intraoperative Complications | 1 | 2004 | 1161 | 0.140 |
Why?
|
Liver Function Tests | 1 | 2019 | 524 | 0.140 |
Why?
|
Hypolipidemic Agents | 1 | 2021 | 609 | 0.140 |
Why?
|
Aortic Coarctation | 1 | 2019 | 275 | 0.140 |
Why?
|
Comorbidity | 7 | 2018 | 10505 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 548 | 0.140 |
Why?
|
Sex Factors | 4 | 2019 | 10548 | 0.130 |
Why?
|
Insulin Resistance | 3 | 2017 | 3954 | 0.130 |
Why?
|
Health Status Disparities | 2 | 2019 | 1846 | 0.130 |
Why?
|
Educational Status | 1 | 2024 | 2509 | 0.130 |
Why?
|
Public Health | 3 | 2020 | 2669 | 0.130 |
Why?
|
Incidence | 8 | 2021 | 21337 | 0.130 |
Why?
|
Private Sector | 1 | 2019 | 394 | 0.130 |
Why?
|
Pacemaker, Artificial | 1 | 2021 | 805 | 0.130 |
Why?
|
India | 1 | 2022 | 2286 | 0.130 |
Why?
|
Coronary Disease | 4 | 2023 | 5912 | 0.130 |
Why?
|
Expert Testimony | 1 | 2018 | 364 | 0.130 |
Why?
|
Financing, Government | 1 | 2019 | 472 | 0.130 |
Why?
|
Developmental Disabilities | 1 | 2004 | 1509 | 0.120 |
Why?
|
Censuses | 1 | 2016 | 198 | 0.120 |
Why?
|
Aorta | 2 | 2022 | 2041 | 0.120 |
Why?
|
Forecasting | 1 | 2024 | 2924 | 0.120 |
Why?
|
Morbidity | 1 | 2020 | 1750 | 0.120 |
Why?
|
Lipodystrophy | 1 | 2016 | 145 | 0.120 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2016 | 292 | 0.120 |
Why?
|
Research Subjects | 1 | 2017 | 249 | 0.120 |
Why?
|
Societies, Medical | 4 | 2019 | 3900 | 0.120 |
Why?
|
Heart Valve Diseases | 1 | 2022 | 1028 | 0.120 |
Why?
|
Glycerol Kinase | 1 | 2014 | 17 | 0.120 |
Why?
|
Focus Groups | 1 | 2020 | 1409 | 0.120 |
Why?
|
Genetic Counseling | 1 | 2018 | 627 | 0.120 |
Why?
|
Glycerol-3-Phosphate Dehydrogenase (NAD+) | 1 | 2014 | 11 | 0.120 |
Why?
|
Carbohydrate Metabolism, Inborn Errors | 1 | 2014 | 32 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1186 | 0.120 |
Why?
|
Glucose | 2 | 2022 | 4345 | 0.120 |
Why?
|
Hepatomegaly | 1 | 2014 | 84 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2020 | 10199 | 0.110 |
Why?
|
Drug Recalls | 1 | 2013 | 20 | 0.110 |
Why?
|
Middle Aged | 15 | 2024 | 220584 | 0.110 |
Why?
|
Benchmarking | 2 | 2018 | 1045 | 0.110 |
Why?
|
Perception | 1 | 2020 | 1198 | 0.110 |
Why?
|
Utilization Review | 1 | 2015 | 382 | 0.110 |
Why?
|
Decision Making | 3 | 2016 | 3918 | 0.110 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2024 | 1553 | 0.110 |
Why?
|
Neoplasms | 1 | 2022 | 22131 | 0.110 |
Why?
|
Nervous System Diseases | 1 | 2004 | 1662 | 0.110 |
Why?
|
Inflammation | 3 | 2023 | 10760 | 0.110 |
Why?
|
Patient Identification Systems | 1 | 2013 | 75 | 0.110 |
Why?
|
Burnout, Professional | 1 | 2022 | 703 | 0.110 |
Why?
|
Down-Regulation | 2 | 2020 | 2915 | 0.110 |
Why?
|
Ventricular Function, Left | 4 | 2022 | 3873 | 0.110 |
Why?
|
Health Planning Guidelines | 1 | 2013 | 151 | 0.110 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12043 | 0.110 |
Why?
|
Serine Endopeptidases | 2 | 2016 | 1022 | 0.110 |
Why?
|
Cities | 1 | 2015 | 546 | 0.110 |
Why?
|
Risk | 5 | 2019 | 9604 | 0.100 |
Why?
|
Data Interpretation, Statistical | 4 | 2018 | 2689 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3088 | 0.100 |
Why?
|
Drug Contamination | 1 | 2013 | 151 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3209 | 0.100 |
Why?
|
Parents | 5 | 2017 | 3563 | 0.100 |
Why?
|
Nephrotic Syndrome | 1 | 2016 | 390 | 0.100 |
Why?
|
Defibrillators, Implantable | 1 | 2021 | 1483 | 0.100 |
Why?
|
Massachusetts | 3 | 2021 | 8833 | 0.100 |
Why?
|
Heptanoic Acids | 1 | 2013 | 344 | 0.100 |
Why?
|
Motivation | 1 | 2021 | 2003 | 0.100 |
Why?
|
Blood Glucose | 4 | 2017 | 6390 | 0.100 |
Why?
|
Aspirin | 2 | 2019 | 3127 | 0.100 |
Why?
|
Lipid Metabolism | 2 | 2012 | 1896 | 0.100 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 2003 | 0.100 |
Why?
|
Fasting | 3 | 2007 | 1603 | 0.090 |
Why?
|
Cooperative Behavior | 1 | 2018 | 1504 | 0.090 |
Why?
|
Circadian Rhythm | 1 | 2023 | 2569 | 0.090 |
Why?
|
Regression Analysis | 3 | 2019 | 6338 | 0.090 |
Why?
|
Primary Health Care | 3 | 2016 | 4668 | 0.090 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 708 | 0.090 |
Why?
|
Patient Care | 1 | 2016 | 621 | 0.090 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2011 | 118 | 0.090 |
Why?
|
Social Class | 1 | 2019 | 1992 | 0.090 |
Why?
|
Tunica Media | 1 | 2010 | 112 | 0.090 |
Why?
|
Pilot Projects | 3 | 2024 | 8618 | 0.080 |
Why?
|
Guidelines as Topic | 2 | 2016 | 1386 | 0.080 |
Why?
|
Remission, Spontaneous | 1 | 2010 | 384 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7798 | 0.080 |
Why?
|
Exercise | 4 | 2023 | 5886 | 0.080 |
Why?
|
Child Health Services | 2 | 2013 | 644 | 0.080 |
Why?
|
Logistic Models | 3 | 2021 | 13245 | 0.080 |
Why?
|
Population Surveillance | 1 | 2020 | 2595 | 0.080 |
Why?
|
Health Services Accessibility | 2 | 2024 | 5430 | 0.080 |
Why?
|
Diabetic Angiopathies | 1 | 2014 | 803 | 0.080 |
Why?
|
Health Services Research | 1 | 2017 | 1808 | 0.080 |
Why?
|
Length of Stay | 2 | 2021 | 6418 | 0.080 |
Why?
|
Sinusitis | 1 | 1998 | 991 | 0.080 |
Why?
|
Anion Exchange Resins | 1 | 2008 | 10 | 0.080 |
Why?
|
Insulin | 3 | 2022 | 6593 | 0.080 |
Why?
|
Cardiac Surgical Procedures | 1 | 2004 | 3621 | 0.080 |
Why?
|
Drug Therapy | 1 | 2012 | 503 | 0.080 |
Why?
|
Anticoagulants | 3 | 2020 | 4785 | 0.080 |
Why?
|
Cause of Death | 1 | 2019 | 3683 | 0.080 |
Why?
|
Reference Values | 3 | 2017 | 4919 | 0.080 |
Why?
|
Breast Feeding | 1 | 2016 | 1354 | 0.080 |
Why?
|
Tunica Intima | 1 | 2010 | 459 | 0.070 |
Why?
|
Disease Progression | 4 | 2022 | 13495 | 0.070 |
Why?
|
Leptin | 1 | 2016 | 1595 | 0.070 |
Why?
|
Hyperemia | 1 | 2009 | 221 | 0.070 |
Why?
|
Fatty Liver | 1 | 2014 | 787 | 0.070 |
Why?
|
Medication Therapy Management | 2 | 2018 | 130 | 0.070 |
Why?
|
Anthropometry | 2 | 2019 | 1338 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1866 | 0.070 |
Why?
|
Ambulatory Care | 1 | 2018 | 2768 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2017 | 1669 | 0.070 |
Why?
|
Pyrroles | 1 | 2013 | 1125 | 0.070 |
Why?
|
Clinical Protocols | 1 | 2013 | 1437 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2014 | 2423 | 0.070 |
Why?
|
Motor Activity | 2 | 2016 | 2714 | 0.070 |
Why?
|
Patient Care Planning | 1 | 2012 | 905 | 0.070 |
Why?
|
Regional Blood Flow | 1 | 2010 | 1496 | 0.070 |
Why?
|
Cost of Illness | 3 | 2024 | 1935 | 0.070 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2008 | 393 | 0.070 |
Why?
|
Clinical Trials as Topic | 3 | 2019 | 7995 | 0.070 |
Why?
|
Postprandial Period | 1 | 2008 | 314 | 0.070 |
Why?
|
Cell Size | 1 | 2008 | 624 | 0.070 |
Why?
|
Adipokines | 1 | 2008 | 308 | 0.060 |
Why?
|
Myocardium | 2 | 2022 | 4724 | 0.060 |
Why?
|
Fingers | 1 | 2009 | 506 | 0.060 |
Why?
|
Aged | 9 | 2024 | 169042 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17878 | 0.060 |
Why?
|
Carotid Arteries | 1 | 2010 | 941 | 0.060 |
Why?
|
Students | 1 | 2015 | 1733 | 0.060 |
Why?
|
Quality Improvement | 2 | 2018 | 3797 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2012 | 1469 | 0.060 |
Why?
|
Pregnancy | 3 | 2023 | 29868 | 0.060 |
Why?
|
Weight Loss | 1 | 2017 | 2682 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12447 | 0.060 |
Why?
|
Time Factors | 4 | 2021 | 39913 | 0.060 |
Why?
|
Phenotype | 5 | 2024 | 16571 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 6174 | 0.060 |
Why?
|
Pandemics | 5 | 2022 | 8645 | 0.060 |
Why?
|
Hyperlipoproteinemia Type I | 1 | 2024 | 11 | 0.060 |
Why?
|
Receptors, LDL | 2 | 2018 | 488 | 0.060 |
Why?
|
Feasibility Studies | 2 | 2020 | 5239 | 0.060 |
Why?
|
Inflammation Mediators | 2 | 2013 | 1884 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9172 | 0.050 |
Why?
|
Case-Control Studies | 5 | 2021 | 22148 | 0.050 |
Why?
|
Internet | 1 | 2015 | 3090 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10754 | 0.050 |
Why?
|
Waist Circumference | 2 | 2017 | 933 | 0.050 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 2024 | 140 | 0.050 |
Why?
|
Steroid 12-alpha-Hydroxylase | 1 | 2022 | 9 | 0.050 |
Why?
|
Animals | 7 | 2022 | 168201 | 0.050 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2315 | 0.050 |
Why?
|
Endoplasmic Reticulum | 1 | 2008 | 1132 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10704 | 0.050 |
Why?
|
Sitosterols | 1 | 2020 | 8 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7871 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20074 | 0.050 |
Why?
|
MicroRNAs | 1 | 2017 | 3805 | 0.050 |
Why?
|
Immunologic Factors | 2 | 2020 | 1589 | 0.040 |
Why?
|
Phytosterols | 1 | 2020 | 55 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2022 | 15251 | 0.040 |
Why?
|
Electronic Health Records | 2 | 2017 | 4803 | 0.040 |
Why?
|
Xanthomatosis | 1 | 2020 | 32 | 0.040 |
Why?
|
New Zealand | 1 | 2020 | 358 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15828 | 0.040 |
Why?
|
Lipoproteins, HDL | 1 | 2004 | 675 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2014 | 12334 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 1998 | 7402 | 0.040 |
Why?
|
Terminology as Topic | 2 | 2017 | 1528 | 0.040 |
Why?
|
Bile Acids and Salts | 1 | 2022 | 393 | 0.040 |
Why?
|
Neonatal Screening | 1 | 2024 | 597 | 0.040 |
Why?
|
Macrophage Activation Syndrome | 1 | 2020 | 124 | 0.040 |
Why?
|
Simvastatin | 1 | 2022 | 346 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 612 | 0.040 |
Why?
|
Cardiac Imaging Techniques | 1 | 2021 | 266 | 0.040 |
Why?
|
Lipoprotein(a) | 1 | 2024 | 479 | 0.040 |
Why?
|
Cohort Studies | 5 | 2024 | 41457 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3426 | 0.040 |
Why?
|
Pain Measurement | 1 | 2009 | 3546 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
Liver | 3 | 2022 | 7512 | 0.040 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2017 | 1048 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2022 | 544 | 0.040 |
Why?
|
Troponin | 1 | 2021 | 502 | 0.040 |
Why?
|
Receptor, Insulin | 1 | 2022 | 836 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2023 | 911 | 0.040 |
Why?
|
Arteriosclerosis | 1 | 2002 | 1056 | 0.040 |
Why?
|
Legislation, Drug | 1 | 2019 | 214 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3599 | 0.040 |
Why?
|
Coronary Vessel Anomalies | 1 | 2020 | 307 | 0.040 |
Why?
|
Amoxicillin | 1 | 1998 | 180 | 0.040 |
Why?
|
Organizational Policy | 1 | 2019 | 431 | 0.040 |
Why?
|
Australia | 1 | 2020 | 1248 | 0.030 |
Why?
|
Gadolinium | 1 | 2022 | 959 | 0.030 |
Why?
|
Mississippi | 1 | 2017 | 95 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2008 | 2878 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2008 | 3113 | 0.030 |
Why?
|
Food Safety | 1 | 2016 | 22 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2023 | 1738 | 0.030 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 1 | 2016 | 62 | 0.030 |
Why?
|
Hemorrhage | 2 | 2020 | 3418 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2020 | 599 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2007 | 6807 | 0.030 |
Why?
|
Qualitative Research | 2 | 2017 | 3016 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2022 | 2079 | 0.030 |
Why?
|
Quality Control | 1 | 1998 | 831 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 12978 | 0.030 |
Why?
|
Steroids | 1 | 2020 | 929 | 0.030 |
Why?
|
International Normalized Ratio | 1 | 2017 | 381 | 0.030 |
Why?
|
Prognosis | 3 | 2021 | 29600 | 0.030 |
Why?
|
Penicillins | 1 | 1998 | 402 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1172 | 0.030 |
Why?
|
California | 1 | 2019 | 1430 | 0.030 |
Why?
|
Mice, Obese | 1 | 2016 | 418 | 0.030 |
Why?
|
Smoking Cessation | 2 | 2017 | 2056 | 0.030 |
Why?
|
Mitochondria | 1 | 2008 | 3619 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58894 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14018 | 0.030 |
Why?
|
Stroke Volume | 2 | 2021 | 5486 | 0.030 |
Why?
|
Carnitine O-Palmitoyltransferase | 1 | 2014 | 82 | 0.030 |
Why?
|
Diet | 2 | 2024 | 8048 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1594 | 0.030 |
Why?
|
Social Change | 1 | 2013 | 153 | 0.030 |
Why?
|
Smoking | 2 | 2017 | 9050 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 11669 | 0.030 |
Why?
|
Drug Approval | 1 | 2019 | 812 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2008 | 10432 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2189 | 0.030 |
Why?
|
Liver Transplantation | 1 | 2024 | 2329 | 0.020 |
Why?
|
School Health Services | 1 | 2015 | 384 | 0.020 |
Why?
|
Podocytes | 1 | 2016 | 405 | 0.020 |
Why?
|
Chronic Disease | 2 | 2017 | 9311 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2017 | 1242 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1723 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3769 | 0.020 |
Why?
|
History, 20th Century | 1 | 2019 | 2764 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 1996 | 1380 | 0.020 |
Why?
|
Research Personnel | 1 | 2016 | 588 | 0.020 |
Why?
|
Organ Size | 1 | 2016 | 2252 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14591 | 0.020 |
Why?
|
Self Care | 1 | 2016 | 796 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1661 | 0.020 |
Why?
|
Physical Fitness | 1 | 2015 | 743 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2020 | 3206 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6305 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3836 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2160 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1365 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2019 | 2090 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5866 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2016 | 1438 | 0.020 |
Why?
|
Contrast Media | 1 | 2022 | 5305 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2016 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3800 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4570 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7373 | 0.020 |
Why?
|
Electroencephalography | 1 | 2004 | 6237 | 0.020 |
Why?
|
Heart | 1 | 2021 | 4403 | 0.020 |
Why?
|
Electrocardiography | 1 | 2021 | 6346 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5034 | 0.020 |
Why?
|
Vaccines | 1 | 2017 | 838 | 0.020 |
Why?
|
Diabetes Mellitus | 2 | 2017 | 5835 | 0.020 |
Why?
|
Transposition of Great Vessels | 1 | 2012 | 580 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4341 | 0.020 |
Why?
|
Acute Disease | 1 | 1998 | 7237 | 0.020 |
Why?
|
Data Collection | 1 | 2016 | 3315 | 0.020 |
Why?
|
Heterozygote | 1 | 2014 | 2780 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4614 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6520 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2017 | 2637 | 0.020 |
Why?
|
Gene Deletion | 1 | 2014 | 2661 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6474 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3194 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2014 | 2020 | 0.020 |
Why?
|
Child Development | 1 | 2016 | 2300 | 0.020 |
Why?
|
Vaccination | 1 | 2017 | 3370 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 36402 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2016 | 3796 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7568 | 0.010 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2012 | 1310 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4739 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13347 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81368 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14648 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14389 | 0.010 |
Why?
|
Autoanalysis | 1 | 2000 | 71 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5964 | 0.010 |
Why?
|
Surface-Active Agents | 1 | 2000 | 150 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2000 | 239 | 0.010 |
Why?
|
Mutation | 2 | 2014 | 30016 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22115 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 12661 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20556 | 0.010 |
Why?
|
Eating | 1 | 2000 | 1535 | 0.010 |
Why?
|
Brain | 1 | 2016 | 27101 | 0.010 |
Why?
|
Models, Statistical | 1 | 1996 | 5073 | 0.000 |
Why?
|